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Supplementation with carnitine for weight loss: a biochemical approach
José Henry Osorio, PhD*
SUMMARY
Carnitine is a molecule involved in transporting activated fatty acids among different cellular compartments, which is most
likely present in all animal species, and in numerous microorganisms and plants. Recently the trend in the field of weight
control is to include carnitine in the diet as an agent responsible for weight loss. In the present review, some findings are
discussed from a biochemical point of view to illustrate if the use of carnitine for weight loss can be considered fiction or
reality.
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Suplementación con carnitina para perder peso: Una aproximación bioquímica
RESUMEN
La carnitina es una molécula involucrada en el transporte de ácidos grasos activados, entre diferentes compartimentos
celulares, la cual posiblemente está presente en todas las especies animales, así como en numerosos microorganismos y
plantas. Recientemente, la tendencia en el campo del control de peso incluye la introducción de carnitina en la dieta, como
un agente responsable de la pérdida de peso. En el presente artículo de revisión, se discuten algunos hallazgos, desde un punto
de vista bioquímico, para ilustrar si el uso de carnitina para la pérdida de peso puede considerarse ficción o realidad.
Palabras clave: Carnitina; Metabolismo lipídico; Pérdida de peso. 
Colomb Med. 2011; 42: 529-35
Recently, an increasing number of people believe
that carnitine is an important substance, which can be
supplemented in diets for weight loss in humans, as
well as in pets; hence, it is common to find in the
marketplace a variety of products supplemented with
carnitine or even pure carnitine to consume for weight
loss purposes; however, many doubts remain in the
field of nutrition related to the veracity of this postulate,
making it necessary to delve into the metabolic ways in
which this molecule is implicated.
Carnitine was discovered in muscle extracts and
reported separately in 1905. Its molecular structure (3-
hydroxy-4-N-trimethyl-aminobutyric acid) was
established in 1927 and the name carnitine originates
from the Latin word for flesh or meat, carno.
In 1952, Carter et al.1, found that carnitine was
essential for the growth of the yellow mealworm,
Tenebrio molitor, and it was also discovered that
carnitine was present in a wide range of biological
materials and that carnitine could be reversibly
acetylated with acetyl-coenzyme A (CoA).
Carnitine is present in tissues and body fluids as free
and as esterified short-chain, medium-chain, and long-
chain acylcarnitines. Total carnitine consists of the sum
of free carnitine and all acylcarnitines. Animal tissues
contain relatively large amounts of carnitine, varying
between 0.2 and 6 μmol/g, with the highest concen-
trations in heart and skeletal muscle2.
The role of carnitine in fatty acid oxidation was
discovered in 1955, while working with liver homo-
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genates, and the configuration of the physiological
enantiomer was determined as L(-) or R(-)-3-hydroxy-
4-N,N,N-trimethylaminobutyrate by Kaneko and
Yoshida in 19623. The main function of carnitine is to
shuttle activated long-chain fatty acids [fatty acyl-
coenzyme A (CoA)] from the cytosol into the
mitochondrial matrix for β-oxidation, and to remove
short-chain, medium-chain, and long-chain fatty acids
that accumulate as a result of normal and abnormal
metabolism4. Thereby, carnitine helps to maintain
adequate cellular levels of free CoA; furthermore,
products from the peroxisomal β-oxidation system,
including acetyl-CoA, are transported as carnitine-
esters from peroxisomes to mitochondria for complete
degradation to CO2 and H2O. Carnitine can also modulate
the toxic effects of poorly metabolised acyl-groups of
either xenobiotic origin (e.g. pivalic acid and valproate)
or those arising from various inborn errors of meta-
bolism, and it can also interact with membranes to
change their physiochemical properties5. This means
that carnitine modulates the acyl-CoA/free CoA ratio
via the formation of acyl-carnitines. If acyl-CoAs are
produced faster than they are utilised, intramitochondrial
free CoA is regenerated as carnitine, which binds the
acyl-groups, thus, restoring the normal intra-mito-
chondrial acyl-CoA/free CoA ratio6.
The present review analyses the use of carnitine for
fat burning, remarking the main biochemical aspects
related to the subject. First of all, the way fat is physio-
logically burnt by the normal organism is studied, and
two more sections are included, one section shows the
sources of carnitine for humans and the destiny of
carnitine under different conditions, and the latter section
analyses the supplementation of carnitine for weight
loss.
DEGRADATION OF FATTY ACIDS
Fatty acids (FA) are stored in adipose tissue during
periods of good feeding, and they are the major source
of energy for the heart and the skeletal muscle, and one
of the most important processes for producing fuel
during endurance exercise and starvation. FA provide
as much as 80% of the energy for heart and liver
function, and the oxidation of long-chain FA also
provides the energy for non-shivering thermogenesis
by brown adipose tissue7. The study of FA biological
degradation was done in 1904 when Knoop performed
experiments with dogs, which led him to formulate the
theory of β-oxidation. This pathway is responsible for
the degradation of FA to produce acetyl-CoA, and the
mitochondrial location of this pathway agreed with the
observed coupling of FA oxidation to the citric acid
cycle and to oxidative phosphorylation8.
Most tissues are able to degrade FA to CO2 and H2O,
but the liver has the unique capacity to synthesise
ketone bodies, acetoacetate and 3-hydroxybutyrate from
acetyl-CoA, supplying an important fuel to other organs,
mainly the brain9.
In addition, peroxisomes and glyoxysomes,
collectively referred to as micro bodies, are sub-cellular
organelles that do not have an energy-coupled electron
transport system, but instead contain flavine oxidases,
which catalyse the substrate-dependent reduction of
oxygen to H2O2. Within a few years of the identification
of peroxisomal β-oxidation in animals, the pathway
was elucidated and the liver enzymes had been purified
and characterised10. FA are activated by acyl-CoA
synthetase on the peroxisomal membrane and the entry
into the organelle is independent of carnitine. Substrates
that are preferably, or exclusively, oxidised in pero-
xisomes include very long-chain FA, polyunsaturated
FA, dicarboxylic acids, prostaglandins, eicosanoids,
pristanic acid, bile acid intermediates, and side chains
of xenobiotics, which are not metabolised or poorly
metabolised by mitochondria, and the side chain of
cholesterol11.
The mitochondrial β-oxidation pathway. Physiolo-
gically available FA are mostly C16 and C18 species
and include saturated and both mono- and di-unsaturated
species. The tissue uptake of FA and their transfer from
the cell membrane to the place of β-oxidation remain
poorly understood. FA transporters (FATP) and
cytosolic FA-binding proteins (FABP) are probably
involved in these processes12.
For mitochondrial β-oxidation, long-chain FA are
activated to their CoA esters by Acyl-CoA synthase in
the cytosol and on the mitochondrial outer membrane;
the mitochondrial inner membrane is impermeable to
acyl-CoA esters. Carnitine is supplied into the cell by a
plasma membrane carnitine transporter commonly
referred to as OCTN2, located in the cellular membrane,
and three enzymes: carnitine palmitoyltransferase I
(CPT I) in the outer mitochondrial membrane; carnitine/
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acylcarnitine translocase (CACT) within the inner
mitochondrial membrane, and carnitine palmitoyl-
transferase (CPT II) in the inner mitochondrial mem-
brane (carnitine O-palmitoyltransferase EC 2.3.1.21)
are responsible for the reversible reaction: acyl-
CoA+carnitine=acylcarnitine+CoA-SH. The regulation
of mitochondrial FA oxidation mainly involves CPT I.
In the liver, CPT I controls the FA flux through the
esterification and oxidative pathways, given its
sensitivity to malonyl-CoA, a potent CPT I inhibitor
that is the first committed intermediate in the pathway
of FA biosynthesis13. During fasting, the malonyl-CoA
level decreases, and CPT I becomes uninhibited, then
long-chain fatty acid (LCFA) oxidation and subsequent
ketogenesis become enhanced. In the post-absorptive
state, the concentration of malonyl-CoA rises, CPT I is
thereafter inhibited, and newly formed LCFA are
directed towards esterification. Fatty Acids of less than
12 carbons, such as those provided by dietary
supplements of medium-chain triglycerides, can enter
the mitochondria and are activated within the
mitochondrial matrix independent of the carnitine
transport system14.
The β-oxidation spiral. Once inside the mito-
chondria, the fatty acyl-CoA is degraded through four
separate reactions. The enzyme responsible for the first
step is an acyl-CoA dehydrogenase, which transfers the
electrons to an electron-transfer flavoprotein (ETF)
and Coenzyme Q of the respiratory chain by using a
second flavoprotein ETF: CoQ oxidorreductase, also
named ETF dehydrogenase.
The second step is carried out by an enoyl-CoA
hydratase, and the enzyme involved in the third step is
an L 3-hydroxyacyl-CoA dehydrogenase using NAD as
cofactor for the reaction, which is reduced to NADH
transferring electrons to complex 1 of the respiratory
chain. After the fourth step in which a 3-ketoacyl-CoA
thiolase is involved, cycling continues until the final
thiolytic cleavage with the production of two acetyl-
CoA molecules. The acetyl-CoA produced is used
directly in muscle as an energy substrate through the
citric acid cycle, whilst in the liver it is degraded for the
production of ketone bodies as an energy source in
tissues such as brain15.
The distribution of the enzymes into the mitochondria
is divided in membrane-bound enzymes and mitochon-
drial matrix enzymes.
The enzymes for the b-oxidation of long- to medium-
chain fatty acids (C-18 to C-12) are located close to the
inner mitochondrial membrane, they are: very-long-
chain acyl-CoA dehydrogenase, long-chain enoyl-CoA
hydratase, long-chain L 3-hydroxyacyl-CoA dehydro-
genase and long-chain 3-ketoacyl-CoA thiolase. The
activity for the last three enzymes is found within a
multiple complex known as the mitochondrial trifunc-
tional protein (TFP)16.
The enzymes located within the mitochondrial matrix
are responsible for β-oxidation of the medium- to short-
chain acyl-CoA intermediates, including long-chain,
medium-chain, and short-chain acyl-CoA dehydro-
genases; a short-chain hydratase, also named crotonase;
a medium-/short-chain 3-hydroxyacyl-CoA-dehydro-
genase; and both medium-chain and short-chain 3-keto
acyl CoA thiolases17.
Unsaturated FA oxidation requires auxiliary
enzymes. D3,D2-enoyl-CoA isomerase and 2,4-dienoyl-
CoA reductase are the auxiliary enzymes for α-oxidation
of FA with double bond at an odd- and even-numbered
position, respectively (linoleate isomerase E.C.5.2.1.5;
cis-2-enoyl CoA reductase E.C.1.3.1.37; trans-2-enoyl
CoA reductase E.C.1.3.1.38). The above-mentioned
isomerase catalyses the isomerisation of both 3-cis and
3-trans-enoyl-CoAs to 2-trans-enoyl-CoAs. Enoyl-CoA
isomerases for short-, medium- and long-chain substrates
have been identified, and an isoform of mitochondrial
2,4-dienoyl-CoA reductase has been reported18.
Sources of carnitine for humans. Carnitine synthesis
in mammals is carried out from the turnover of proteins
containing lysine residues, which are previously post-
translationally trimethylated with the release of
trimethyllysine. The rate-limiting step in the pathway is
the hepatic enzyme, γ-butyrobetaine hydroxylase;
however, the rate of carnitine biosynthesis is mainly
determined by the rate of protein turnover that supplies
trimethyllysine19.
In humans, 98% of the carnitine resides in the
skeletal and cardiac muscle with 1.6% in the liver and
kidney, and 0.4% in the extra cellular fluid. Humans
obtain most of their carnitine (some 50% to 75% of
daily requirements) through dietary intake (meat,
poultry, fish, and dairy products); with L-carnitine
being primarily synthesised in the liver and also in the
kidney and brain from protein-derived 6-N-trime-
thyllysine via 3-hydroxy-6-N-trimethyllysine, 4-N-
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trimethylaminobutyraldehyde and 4-N trimethylamino-
butyrate (4-N-butyrobetaine). Other cells depend on
carnitine import via active uptake from the blood. This
transport system is also involved in the renal tubular re-
absorption and intestinal absorption of carnitine20.
There is no degradation pathway for carnitine in
mammals, although there is minor degradation of dietary
carnitine by intestinal bacteria (less than 1% to 2% in
total), and carnitine is eliminated via urine as free
carnitine and acylcarnitines with renal fractional re-
absorption of up to 90%. Carnitine uptake into tissues
and cells occurs by a saturable sodium-dependent
transport mechanism21, and a failure of its transport
mechanism leads to systemic or primary carnitine
deficiency associated with low levels of free and total
carnitine in tissues and plasma. Also, during periods of
metabolic decompensation in which acyl-CoA esters
accumulate, the concentration of acylcarnitines greatly
increases and exceeds the capacity for L-carnitine
biosynthesis (and of dietary sources), leading to a
secondary carnitine deficiency22.
Supplementation with carnitine. It has been
scientifically recognized that carnitine can be supple-
mented to improve some clinical conditions like ano-
rexia23; cardiovascular disease, angina and ischemia24;
cardiogenic shock25; cardiomyopathy26,27; myocardial
infarction28; hyperlipidemia29; insulin resistance30;
painful diabetic neuropathy31; chronic fatigue
syndrome32; fatty liver33; hepatitis and hepatic ence-
phalopathy34; immunity problems35; hyperthyroidism36;
male infertility37; renal failure/dialysis38,39; respiratory
distress in premature infants40, and inherited inborn
errors of fatty-acid oxidation41.
The levels of endogenous L- carnitine, under normal
conditions, can be influenced by long-term changes in
dietary habits and nutritional status42, some authors
pointed out that inasmuch as carnitine is not considered
a true ‘vitamin’ and, under normal conditions, healthy
humans can synthesise sufficient amounts of it43,
individuals who consumed diets low in L-carnitine
(vegetarian diets) had lower plasma L-carnitine levels
than subjects consuming a mixed diet, with children
being affected to a greater extent than adults. Despite
large variations in dietary intake, the mean plasma
levels of the compound vary by only about 20%. This
is understandable as renal excretion of L-carnitine is
substantially less in those individuals with low dietary
intake42. Therefore, carnitine biosynthesis and renal
conservation mechanisms are generally implicated and
adequate to prevent overt carnitine deficiency in
individuals who self-select diets that are low in
carnitine42.
Dietary L-carnitine intake can vary significantly
between strict vegetarians who consume less than 0.1
ìmol/kg/day, representing about 1 mg/day for a 70-kg
adult, and an average person with a diet providing a
daily intake of 2-12 μmol/ kg/day, or 23-135 mg per day
for an average adult44; however, the extent of absorption
in the subjects fed with a low-carnitine diet may be
75%, on average45 while in subjects on a high-carnitine
diet, 37% of the dose can be accounted for as excreted
metabolites, meaning that the extent of absorption
might be about 63%. Then the efficiency of absorption
tends to diminish as the carnitine content of the diet
increases45,46, reflecting the involvement of specific
transporters that can be saturated even with normal
dietary intake. On the other hand, the bioavailability of
supplemental or medicinal oral doses of L-carnitine
tends to be even lower, at 5%-18%. Loss of endogenous
L-carnitine from the body primarily occurs via renal
excretion in the form of L-carnitine, acetyl-L-carnitine
and longer chain esters. In a 24-hour period, a healthy
human consuming a normal diet excretes between 100
and 300 μmol of total carnitine, although the overall
rate of excretion varies according to dietary intake47.
Because L-carnitine is not bound to plasma protein48, it
is extensively filtered at the glomerulus. However,
tubular re-absorption ensures that only a small fraction
of the filtered load is excreted in urine. In healthy
individuals, the fractional tubular re-absorption of L-
carnitine (and acyl-L-carnitine derivatives) exceeds
90% and is probably greater than 98% under normal
homeostatic conditions49,50. If the tubular re-absorption
of L-carnitine is impaired due to disease or the
administration of compounds that inhibit the renal
tubular transport of the compound, the result is an
increased urinary loss, and a systemic deficiency may
develop51,52. In renal Fanconi syndrome, a significant
reduction in the tubular re-absorption of L-carnitine
results in a secondary deficiency of L-carnitine in
plasma and muscle53. In some specific cases like training
and exercise, the information obtained is somewhat
controversial, given that some authors have found
evidence for a beneficial effect of L-carnitine
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supplementation during training, competition, and
recovery from strenuous exercise and during regene-
rative athletics54, in contrast to others55,56; however,
experimental findings support the statement that L-
carnitine supplementation does not promote weight
loss57-60.
CONCLUSIONS
After detailed analysis of the biochemical means in
which carnitine is implicated, it can be concluded that
carnitine supplementation does not promote weight
loss and that carnitine supplementation is only reco-
mmended in secondary carnitine deficiency and some
inherited inborn errors based on some important
positions:
· Carnitine is a very important osmolite needed to
import long-chain fatty acids into mitochondria for
β-oxidation. However, the homeostasis of carnitine
is kept through very efficient mechanisms such as
the ability of the human body to synthesize sufficient
amounts of carnitine even under adverse dietetic
management and a very efficient tubular re-
absorption of carnitine under normal conditions.
· The carnitine cycle depends basically on a good
production and an adequate function of the enzymes
carnitine palmiotyl transferase I, carnitine acyl-
carnitine translocase, and carnitine palmitoyl
transferase II, whose production is not stimulated by
carnitine.
· Carnitine does not promote fat degradation and
mobilization from adipose tissue to others tissues
for energy production, as can be achieved by some
hormones like glucagon.
· Negative changes in the efficiency of absorption of
carnitine are present when the content of carnitine in
the diet increases.
REFERENCES
1. Winter SC. Treatment of carnitine deficiency. J Inherit Metab
Dis. 2003; 26: 171-80.
2. Matera M, Bellinghieri G, Costantino G, Santoro D, Calvani
M, Savica V. History of L-carnitine: implications for renal
disease. J Ren Nutr. 2003; 13: 2-14.
3. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of
L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad
Sci. 2004; 1033: 30-41.
4. Rebouche C. Carnitine. In: Shils M, Shike M, Ross A, et al.
Modern nutrition in health and disease. Philadelphia:
Lippincott, Williams and Wilkins; 2006. p. 537-44.
5. Wanders RJA, Vreken P, Ferdinandusse S, Jansen GA,
Waterham HR, van Roermund CWT, et al. Peroxisomal fatty
acid α- and β-oxidation in humans: enzymology, peroxisomal
metabolite transporters and peroxisomal diseases. Biochem
Soc Trans. 2001; 29: 250-67.
6. Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti
P, et al. Carnitine: an osmolyte that plays a metabolic role. J
Cell Biochem. 2000; 80: 1-10.
7. Pessayre D. Role of mitochondria in non-alcoholic fatty liver
disease. J Gastroenterol Hepatol. 2007; 22( Suppl 1): S20-7.
8. Eaton S, Fukumoto K, Stefanutti G, Spitz L, Zammit VA,
Pierro A. Myocardial carnitine palmitoyltransferase I as a
target for oxidative modification in inflammation and sepsis.
Biochem Soc Trans. 2003; 31: 1133-6.
9. Crill CM, Helms RA. The use of carnitine in pediatric nutrition.
Nutr Clin Pract. 2007; 22: 204-13.
10. Poirier Y, Antonenkov VD, Glumoff T, Hiltunen JK.
Peroxisomal beta-oxidation-a metabolic pathway with multiple
functions. Biochim Biophys Acta. 2006; 1763: 1413-26.
11. Wanders RJ, Ferdinandusse S, Brites P, Kemp S. Peroxisomes,
lipid metabolism and lipotoxicity. Biochim Biophys Acta.
2010; 1801: 272-80.
12. Dutta-Roy AK. Cellular uptake of long-chain fatty acids: role
of membrane-associated fatty-acid-binding/transport proteins.
Cell Mol Life Sci. 2000; 57:1360-72.
13. McGarry JD. Travels with carnitine palmitoyltransferase I:
from liver to germ cell with stops in between. Biochem Soc
Trans. 2001; 29: 241-5.
14. Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y. Fatty
acid metabolism, the central nervous system, and feeding.
Obesity. 2006; 14 (Suppl 5): S201-7.
15. Baker A, Graham IA, Holdsworth M, Smith SM, Theodoulou
FL. Chewing the fat: beta-oxidation in signaling and
development. Trends Plant Sci. 2006; 11: 124-32.
16. Demizieux L. Control and regulation of mitochondrial
oxidation of long-chained fatty acids. J Soc Biol. 2005; 199:
143-55.
17. Bennet MJ, Rinaldo P, Strauss AW. Inborn errors of mito-
chondrial fatty acid oxidation. Clin Rev Clin Lab Sci. 2000;
37: 1-44.
18. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower
serum triglycerides? Curr Opin Lipidol. 2006; 17: 387-93.
19. Czeczot H, Scibior D. Role of L-carnitine in metabolism,
nutrition and therapy. Postepy Hig Med Dosw. 2005; 59: 9-19.
20. Longo N, Amat di San Filippo C, Pasquali M. Disorders of
carnitine transport and the carnitine cycle. Am J Med Genet C
Semin Med Genet. 2006; 142C: 77-85.
21. Labadaridis J, Mavridou I, Sarafidou G, Alexiou N, Costalos
C, Michelakakis H.  Carnitine supplementation and ketogenesis
by small-for-date neonates on medium-and long-chain fatty
acid formulae. Biol Neonate. 2000; 77: 25-8.
22. Infante JP, Huszagh VA. Secondary carnitine deficiency and
impaired docosahexaenoic (22:6n-3) acid synthesis: a common
denominator in the pathophysiology of diseases of oxidative
534
Colombia Médica                  Vol. 42 Nº 4, 2011 (Octubre-Diciembre)
phosphorilation and β-oxidation. FEBS letters. 2000; 468: 1-
5.
23. Laviano A, Meguid MM, Guijarro A, Muscaritoli M, Cascino
A, Preziosa I, et al. Antimyopathic effects of carnitine and
nicotine. Curr Opin Clin Nutr Metab Care. 2006; 9: 442-8.
24. Iyer RN, Khan AA, Gupta A, Vajifdar BU, Lokhandwala YY.
L-carnitine moderately improves the exercise tolerance in
chronic stable angina. J Assoc Physicians India. 2000; 48:
1050-2.
25. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J,
Lysiak-Szydlowska W. Influence of L-carnitine and its
derivatives on myocardial metabolism and function in ischemic
heart disease and during cardiopulmonary bypass. Cardiovasc
Res. 2001; 51: 21-9.
26. Rizos I. Three-year survival of patients with heart failure
caused by dilated cardiomyopathy and L-carnitine
administration. Am Heart J. 2000; 139: S120-3.
27. Gürlek A, Tutar E, Akçil E, Dinçer I, Erol C, Kocatürk PA,
Oral D. The effects of L-carnitine treatment on left ventricular
function and erythrocyte superoxide dismutase activity in
patients with ischemic cardiomyopathy. Eur J Heart Fail.
2000; 2: 189-93.
28. Gaby AR. Nutritional treatments for acute myocardial
infarction. Altern Med Rev. 2010; 15: 113-23.
29. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A,
Baldassarre D, Birreci A, Koverech A. L-carnitine reduces
plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr
Metab Cardiovasc Dis. 2000; 10: 247-51.
30. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L,
Fogari R. The effect of L-carnitine on plasma lipoprotein(a)
levels in hypercholesterolemic patients with type 2 diabetes
mellitus. Clin Ther. 2003; 25: 1429-39.
31. Cakir N, Yetkin I, Karakoc A, Karakan T ,  Ayvaz  G,  Arslan
M. L-carnitine in the treatment of painful diabetic neuropathy
and its effect on plasma beta-endorphin levels. Curr Ther Res
Clin Exp. 2000; 61: 871-6.
32. Kuratsune H. Chronic fatigue syndrome. Ryoikibetsu Shokogun
Shirizu. 2000; 32: 531-4.
33. Karanth J, Jeevaratnam K. Effect of carnitine supplementation
on mitochondrial enzymes in liver and skeletal muscle of rat
after dietary lipid manipulation and physical activity. Indian
J Exp Biol. 2010; 48: 503-10.
34. DaVanzo WJ, Ullian ME. L-carnitine administration reverses
acute mental status changes in a chronic hemodialysis patient
with hepatitis C infection. Clin Nephrol. 2002; 57: 402-05.
35. Moretti S, Famularo G, Marcellini S, Boschini A, Santini G,
Trinchieri V, et al. L-carnitine reduces lymphocyte apoptosis
and oxidant stress in HIV-1-infected subjects treated with
zidovudine and didanosine. Antioxid Redox Signal. 2002; 4:
391-403.
36. Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A,
Trimarchi F. Usefulness of L-carnitine, a naturally occurring
peripheral antagonist of thyroid hormone action, in iatrogenic
hyperthyroidism: a randomized, double-blind, placebo-
controlled clinical trial. J Clin Endocrinol Metab. 2001; 86:
3579-94.
37. Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L,
Dondero F, et al. Use of carnitine therapy in selected cases of
male factor infertility: a double-blind crossover trial. Fertil
Steril. 2003; 79: 292-300.
38. Veselá E, Racek J, Trefil L, Jankovy’ch V, Pojer M. Effect of
L-carnitine supplementation in hemodialysis patients. Nephron.
2001; 88: 218-23.
39. Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficial
effects of L-carnitine in dialysis patients with impaired left
ventricular function: an observational study. Curr Med Res
Opin. 2002; 18: 172-5.
40. Whitfield J, Smith T, Sollohub H, Sweetman L, Roe CR.
Clinical effects of L-carnitine supplementation on apnea and
growth in very low birth weight infants. Pediatrics. 2003; 111:
477-82.
41. Peña-Quintana L, Sanjurjo-Crespo P. Diagnostic approach
and treatment of inherited mitochondrial fatty acid oxidation
disorders. An Esp Pediatr. 2001; 55: 524-34.
42. Stanley CA. Carnitine deficiency disorders in children. Ann N
Y Acad Sci 2004; 1033: 42-51.
43. Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals.
Biochem J. 2002; 361: 417-29.
44 Krajcovicová-Kudlácková M, Simoncic R, Béderová A,
Babinská K, Béder I. Correlation of carnitine levels to
methionine and lysine intake. Physiol Res. 2000; 49: 399-402.
45. Pace S, Longo A, Toon S, Rolan P, Evans AM. Pharmaco-
kinetics of propionyl-L-carnitine in humans: evidence for
saturable tubular reabsorption. Br J Clin Pharmacol. 2000;
50: 441-8.
46. Fokkema MR, van Rieke HM, Bauermann OJ, Smit EN,
Muskiet FA. Short-term carnitine supplementation does not
augment LCPomega3 status of vegans and lacto-ovo-
vegetarians. J Am Coll Nutr. 2005; 24: 58-64.
47. Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg
F, Wilcken B. Current issues regarding treatment of
mitochondrial fatty acid oxidation disorders. J Inherit Metab
Dis. 2010; 33: 555-61.
48. Baek JE, Yang WS, Chang JW, Kim SB, Park SK, Park JS, Lee
SK. Fatty acid-bearing albumin induces VCAM-1 expression
through c-Src kinase-AP-1/NF-kB pathways: effect of L-
carnitine. Kidney Blood Press Res. 2010; 33: 72-84.
49. Chapela SP, Kriguer N, Fernández EH, Stella CA. Involvement
of L-carnitine in cellular metabolism: beyond Acyl-CoA
transport. Mini Rev Med Chem. 2009; 9: 1518-26.
50. Karanth J, Jeevaratnam K. Effect of carnitine supplementation
on mitochondrial enzymes in liver and skeletal muscle of rat
after dietary lipid manipulation and physical activity. Indian
J Exp Biol. 2010; 48: 503-10.
51. Laforêt P, Vianey-Saban C. Disorders of muscle lipid
metabolism: diagnostic and therapeutic challenges. Neuro-
muscul Disord. 2010; 20: 693-700.
52. Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for
metabolic myopathies. Curr Neurol Neurosci Rep. 2010; 10:
118-26.
53. Bökenkamp A, Ludwig M. Disorders of the renal proximal
tubule. Nephron Physiol. 2011; 118: 1-6.
54. Karlic H, Lohninger A. Supplementation of L-carnitine in
athletes: does it make sense? Nutrition. 2004; 20: 709-15.
535
Colombia Médica                         Vol. 42 Nº 4, 2011 (Octubre-Diciembre)
55. Jacobs PL, Goldstein ER. Long-term glycine propionyl-l-
carnitine supplemention and paradoxical effects on repeated
anaerobic sprint performance. J Int Soc Sports Nutr. 2010; 7:
35.
56. Kraemer WJ, Volek JS, Dunn-Lewis C. L-carnitine supple-
mentation: influence upon physiological function. Curr Sports
Med Rep. 2008; 7: 218-23.
57. Villani RG, Gannon J, Self M, Rich PA. L-Carnitine
supplementation combined with aerobic training does not
promote weight loss in moderately obese women. Int J Sport
Nutr Exerc Metab. 2000; 10: 199-207.
58. Melton SA, Keenan MJ, Stanciu CE, Hegsted M, Zablah-
Pimentel EM, O’Neil CE, et al. L-carnitine supplementation
does not promote weight loss in ovariectomized rats despite
endurance exercise. Int J Vitam Nutr Res. 2005; 75: 156-60.
59. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Mann JI. Carnitine
does not improve weight loss outcomes in valproate-treated
bipolar patients consuming an energy-restricted, low-fat diet.
Bipolar Disord. 2006; 8 (5 Pt 1): 503-7.
60. Saper RB, Eisenberg DM, Phillips RS. Common dietary
supplements for weight loss. Am Fam Physician. 2004; 70:
1731-8.
